Hisoar Pharma announces share repurchase plan for incentive programs

Zhejiang Hisoar Pharmaceutical (SZSE:002099) announced its plan to repurchase the company's A-shares using its own or self-raised funds, aiming to implement an employee stock ownership or equity incentive plan, with the goal of maintaining shareholders' interests and strengthening investor confidence. The total funds allocated for this repurchase are expected to range from CNY 150 million to CNY 300 million, with the repurchase price not exceeding CNY 7.46 per share. Based on these figures, the company anticipates repurchasing approximately 20.1 to 40.21 million shares, representing 1.24% to 2.48% of the company's total share capital.